Home › Trial NCT05576896
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
- Trial IDNCT05576896
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorNorthwestern University
- Enrollment7
- Start date2022-10-10
- ConditionsStage IV Colorectal Cancer Positive for BRAF V600E Mutation · Colorectal Cancer · Colorectal Cancer Stage IV
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.